Showing 5561-5570 of 10114 results for "".
- Socioeconomic Disparities Tied to HS Diagnoseshttps://practicaldermatology.com/news/socioeconomic-disparities-tied-to-hs-diagnoses/2474703/Patients living in lower socioeconomic neighborhoods are more likely to be diagnosed with hidradenitis suppurativa (HS), according to a new cross-sectional analysis of data from the University of California San Francisco (UCSF) health system.
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- Study Finds Gaps in Lichen Planus Screening and Treatment Among U.S. Dermatologistshttps://practicaldermatology.com/news/study-finds-gaps-in-lichen-planus-screening-and-treatment-among-us-dermatologists/2474421/A new cross-sectional study from George Washington University shows significant variability in how U.S. dermatologists diagnose and manage lichen planus, according to a news release. Surveying over 400 board-certified dermatol
- Metabolomic Signature Predictive of Ocular Side Effects in Dupilumab-Treated AD: Studyhttps://practicaldermatology.com/news/metabolomic-signature-may-predict-ocular-side-effects-in-dupilumab-treated-atopic-dermatitis-study/2474199/New research suggests baseline metabolic differences may help predict which patients with atopic dermatitis (AD) are most likely to develop ocular complications from dupilumab. In findings published in
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- GW SMHS Teledermatology Program Receives Renewed Fundinghttps://practicaldermatology.com/news/gw-smhs-teledermatology-program-receives-renewed-funding/2468756/The George Washington University School of Medicine and Health Sciences Department of Dermatology, in collaboration with the Pennsylvania Avenue Baptist Church and the National Psoriasis Foundation (NPF), announced a renewed funding commitment of $350,000 from Johnson & Johnson in support of
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- Survey: 43% With Acne Worry They'll Never Have Clear Skinhttps://practicaldermatology.com/news/survey-43-acne-worry-theyll-never-have-clear-skin/2467063/Ninety percent of acne sufferers experience daily insecurities related to their acne, and 43% worry they will never have clear skin, according to a new survey conducted by Cutera, Inc. June is Acne Awareness Month, and Cutera said in a press release that the findings of the survey “highli
- Sustained Efficacy Following Treatment With Lebrikizumabhttps://practicaldermatology.com/news/sustained-efficacy-following-treatment-lebrikizumab/2467017/A subset of moderate-to-severe atopic dermatitis (AD) patients who were randomly withdrawn from lebrikizumab maintained a stable EASI 90 response up to Week 52 with negligible remaining lebrikizumab serum concentrations, according to research presented at the Revolutionizing Atopic Dermatitis (RA